首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >Genetic variations in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) gene and the susceptibility to B cell non-Hodgkin lymphoma in Egypt

【24h】

Genetic variations in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) gene and the susceptibility to B cell non-Hodgkin lymphoma in Egypt

机译：肿瘤坏死因子相关凋亡诱导配体受体1（TRAI-R1）基因的遗传变异及对B细胞非霍奇金淋巴瘤的敏感性

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis》 |2019年第2019期|共2页
作者
Khorshied M.; Soliman N.; Bakr S.; Khorshied O.;
展开▼
作者单位

Cairo Univ Giza Egypt;

Cairo Univ Giza Egypt;

Fayoum Univ Al Fayyum Egypt;

Cairo Univ Giza Egypt;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. PCR-SSCP检测非霍奇金淋巴瘤患者骨髓克隆性T细胞受体基因重排及其临床意义 [J] . 徐兵, 田红, 周淑芸癌症（英文版） . 2003,第004期
2. Genetic variations in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) gene and the susceptibility to B cell non-Hodgkin lymphoma in Egypt [J] . Khorshied M., Soliman N., Bakr S., Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2019,第期

机译：肿瘤坏死因子相关凋亡诱导配体受体1（TRAI-R1）基因的遗传变异及对B细胞非霍奇金淋巴瘤的敏感性
3. Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer [J] . VonPawelJ., HarveyJ.H., SpigelD.R., Clinical lung cancer . 2014,第3期

机译：Mapatumumab的II期试验，一种肿瘤坏死因子相关凋亡诱导配体受体1（TRAI-R1）的全人激动剂单克隆抗体，与PACLITAXEL和CAROBOLATIN联合治疗未小的非小细胞肺癌患者
4. Genetic variants in the tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) do not contribute but Death Receptor (DR4) genes may contribute to susceptibility to head and neck cancer in Pakistani population [J] . Sarwar R., Mansoor Q., Farooqi A. A., Cellular and molecular biology . 2015,第8期

机译：肿瘤坏死因子相关的凋亡诱导配体（TRAIL）中的遗传变异没有贡献，但死亡受体（DR4）基因可能对巴基斯坦人群的头颈癌易感性有贡献
5. Effect of Molecular Size of PEGylated tumor necrosis factor factor-related apoptosis apoptosis-inducing ligand(TRAIL) : T The Biological Activity and he Stability [C] . Tae Hyung Kim, Su Young Chae, Seung Min Byun, Annual meeting exposition of the Controlled Release Society . 2009

机译：PEG化肿瘤坏死因子相关细胞凋亡诱导配体（TRAIL）分子大小的影响生物学活性和稳定性
6. Modulation of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors in a human osteoclast model in vitro. [D] . McManus, Stephen. 2011

机译：在人类破骨细胞模型中调节肿瘤坏死因子相关的凋亡诱导配体（TRAIL）受体。
7. The Role of Selected Flavonols in Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor–1 (TRAIL-R1) Expression on Activated RAW 264.7 Macrophages [O] . Monika Warat, Tadeusz Sadowski, Ewelina Szliszka, 2015

机译：选定的黄酮醇在激活的RAW 264.7巨噬细胞中与肿瘤坏死因子相关的凋亡诱导配体受体-1（TRAIL-R1）表达中的作用。
8. The Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors TRAIL-R1 and TRAIL-R2 Have Distinct Cross-linking Requirements for Initiation of Apoptosis and Are Non-redundant in JNK Activation [O] . Frank Mühlenbeck, Pascal Schneider, Jean-Luc Bodmer, 2000

机译：肿瘤坏死因子相关的凋亡诱导的配体受体TREA-R1和TRAIL R2具有不同的交联要求，用于启动细胞凋亡，在JNK激活中是非冗余的
9. Modulators of Response to Tumor Necrosis-Related Apoptosis-Inducing Ligand (TRAIL) Therapy in Ovarian Cancer [R] . Behbakht, K. 2009

机译：肿瘤坏死相关凋亡诱导配体（TRaIL）治疗卵巢癌的调节因子

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号